Literature DB >> 10341278

Myelodysplasia.

M L Heaney1, D W Golde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10341278     DOI： 10.1056/NEJM199905273402107

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  93 in total

1.  38-Year-old woman with increasing fatigue and dyspnea.

Authors:  Sherezade Khambatta; Douglas L Nguyen; Christopher M Wittich
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

2.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

3.  CD123 CAR T cells for the treatment of myelodysplastic syndrome.

Authors:  Brett M Stevens; Wei Zhang; Daniel A Pollyea; Amanda Winters; Jonathan Gutman; Clayton Smith; Elizabeth Budde; Stephen J Forman; Craig T Jordan; Enkhtsetseg Purev
Journal:  Exp Hematol       Date:  2019-05-25       Impact factor: 3.084

4.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Authors:  Li Zhou; Christine McMahon; Tushar Bhagat; Cristina Alencar; Yiting Yu; Melissa Fazzari; Davendra Sohal; Christoph Heuck; Krishna Gundabolu; Chun Ng; Yongkai Mo; Wa Shen; Amittha Wickrema; Guanghui Kong; Ellen Friedman; Lubomir Sokol; Ioannis Mantzaris; Giannis Mantzaris; Andrea Pellagatti; Jacqueline Boultwood; Leonidas C Platanias; Ulrich Steidl; Lei Yan; Jonathan M Yingling; Michael M Lahn; Alan List; Markus Bitzer; Amit Verma
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

5.  Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Authors:  Tony A Navas; Mani Mohindru; Myka Estes; Jing Ying Ma; Lubomir Sokol; Perry Pahanish; Simrit Parmar; Edwin Haghnazari; Li Zhou; Robert Collins; Irene Kerr; Aaron N Nguyen; Yin Xu; Leonidas C Platanias; Alan A List; Linda S Higgins; Amit Verma
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

6.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Authors:  Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles A N Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia A Libermann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-12       Impact factor: 11.205

7.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

8.  Apoptotic rate in patients with myelodisplastic syndrome treated with modulatory compounds of pro-apoptotic cytokines.

Authors:  Elena Moldoveanu; Andreea Moicean; Cristina Vidulescu; Daciana Marta; Adriana Colita
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

9.  Characterization of neutrophils and macrophages from ex vivo-cultured murine bone marrow for morphologic maturation and functional responses by imaging flow cytometry.

Authors:  Margery G H Pelletier; Klaudia Szymczak; Anna M Barbeau; Gianna N Prata; Kevin S O'Fallon; Peter Gaines
Journal:  Methods       Date:  2016-09-20       Impact factor: 3.608

10.  Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.

Authors:  Adam Petrich; Brad Kahl; Howard Bailey; Kyungmann Kim; Nancy Turman; Mark Juckett
Journal:  Leuk Lymphoma       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.